Adagene Inc - ADR Aktie News

- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprie...

- Sanofi to exercise option on third SAFEbody discovery program  and sponsor combination clinical trial with muzastotug

SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chief Strategy Officer, Mickael Chane-Du, will participate in one-on-one investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025, taking place...

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with

- Biotech luminary to mentor C-suite and provide strategic guidance - SAN DIEGO and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. John Maraganore as Executive Advisor. “Adagene is currently breaking a toxicity barrier with their pr...

SAN DIEGO and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at ASCO 2025 in Chicago, IL, May 30 - June 3.

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses